Drug Trial Radar · NCT03000530
A Study to Evaluate SAGE-217 in Participants With Moderate to Severe Major Depressive Disorder
Last checked: Nov 20, 2026Latest source record: Nov 28, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
102
Actual
Start
Dec 7, 2016
Primary completion
Oct 4, 2017
Study completion Nov 8, 2017
Sponsor
- Lead sponsor
- BiogenBiogen (BIIB)
- Sponsor type
- Industry
- First posted
- Dec 22, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a two-part (open-label followed by double-blind) study evaluating the safety, tolerability, pharmacokinetics, and efficacy of SAGE-217 in 102 participants diagnosed with moderate to severe Major Depressive Disorder.
Conditions
- Major Depression
Interventions
SAGE-217Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) - Part ATime frame: Day 1 up to Day 21
- Percentage of Participants With TEAEs, Graded by Severity - Part ATime frame: Day 1 up to Day 21
- Change From Baseline in Basophils - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Basophils to Leukocytes Ratio [Percentage (%)] - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Eosinophils - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Eosinophils to Leukocytes Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Hematocrit - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Hemoglobin - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Lymphocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Lymphocytes to Leukocytes Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Monocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Monocytes to Leukocytes Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Neutrophils - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Neutrophils to Leukocytes Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Platelets - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Erythrocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Reticulocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Leukocytes - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Albumin - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Alkaline Phosphatase - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Alanine Aminotransferase - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Aspartate Aminotransferase - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Bilirubin - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Chloride - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Carbon Dioxide - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Creatinine - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Potassium - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Protein - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Sodium - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Urea Nitrogen - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Activated Partial Thromboplastin Time - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Prothrombin International Normalized Ratio (%) - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Prothrombin Time - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in pH - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline in Specific Gravity - Part ATime frame: Baseline, Day 8, Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline (CFB) in Supine Systolic Blood Pressure - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline (CFB) in Supine Diastolic Blood Pressure - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline (CFB) in Standing Systolic Blood Pressure - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline (CFB) in Standing Diastolic Blood Pressure - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline (CFB) in Heart Rate - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline (CFB) in Respiratory Rate - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline (CFB) in Oral Temperature - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Days 8, 9, 10, 11, 12, 13 and 14 (predose, 1 hour postdose), Day 15/ET, follow-up Day 21, follow-up Day 28
- Change From Baseline (CFB) in Oxygen Saturation - Part ATime frame: Baseline, Day 1 (0.25, 0.5, 1, 2, 12 hours postdose), Days 2, 3, 4, 5, 6 and 7 (predose, 0.25, 0.5, 1, 2, 12 hours postdose), Day 8 (predose, 1 hour postdose)
- Change From Baseline in QT Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
- Change From Baseline in QTcF Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
- Change From Baseline in ECG Mean Heart Rate - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
- Change From Baseline in RR Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
- Change From Baseline in PR Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
- Change From Baseline in QRS Interval - Part ATime frame: Baseline, Days 1, 2, 7, 14 and follow-up Day 21
- Percentage of Participants With a Response of 'Yes' to Any Columbia Suicide Severity Rating Scale (C-SSRS) Suicidal Ideation Item - Part ATime frame: Day 1 up to Day 28
- Change From Baseline in Stanford Sleepiness Scale (SSS) Score at Day 15 - Part ATime frame: Baseline, Day 15
- Change From Baseline in the 17-item Hamilton Rating Scale for Depression (HAM-D) Total Score at Day 15 - Part BTime frame: Baseline, Day 15
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
Sage Investigational Site
Garden Grove, California
Sage Investigational Site
Orlando, Florida
Sage Investigational Site
Atlanta, Georgia
Sage Investigational Site
Lake Charles, Louisiana
Sage Investigational Site
Berlin, New Jersey
Sage Investigational Site
Dayton, Ohio
Sage Investigational Site
Austin, Texas
Sage Investigational Site
Charlottesville, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.